Status:
UNKNOWN
A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib
Eligibility:
All Genders
21+ years
Brief Summary
Imatinib is the current standard treatment for advanced GIST. Previous studies have shown that GIST genotype was associated with treatment outcomes with exon 11 having superior outcome compared with e...
Eligibility Criteria
Inclusion
- Histologic diagnosis of advanced stage or metastatic GIST
- Asian patient (as defined by the investigator)
- First line treatment with imatinib
- Availability of tumor samples for kit mutation analysis
- Availability of tumor response rate and or time to progression data
Exclusion
- \-
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
End Date :
December 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01227746
Start Date
September 1 2011
End Date
December 1 2014
Last Update
January 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore, Singapore